Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃ), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃ for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
IPO Year: 2015
Exchange: NASDAQ
Website: vikingtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
| 9/11/2024 | $80.00 | Overweight | JP Morgan |
| 6/27/2024 | $105.00 | Overweight | Morgan Stanley |
| 5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James |
| 3/26/2024 | $116.00 → $138.00 | Outperform | Oppenheimer |
| 3/7/2024 | $110.00 | Buy | Jefferies |
| 2/28/2024 | $46.00 → $116.00 | Outperform | Oppenheimer |
| 5/31/2023 | $32.00 | Buy | ROTH MKM |
| 3/28/2023 | $15.00 → $25.00 | Buy | Maxim Group |
| 3/17/2023 | $22.00 | Buy | Stifel |
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
10-Q - Viking Therapeutics, Inc. (0001607678) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
H.C. Wainwright reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $102.00 from $90.00 previously
JP Morgan initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $80.00
Morgan Stanley initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $105.00
Raymond James upgraded Viking Therapeutics from Outperform to Strong Buy and set a new price target of $116.00 from $115.00 previously
Oppenheimer reiterated coverage of Viking Therapeutics with a rating of Outperform and set a new price target of $138.00 from $116.00 previously
Jefferies initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $110.00
Oppenheimer reiterated coverage of Viking Therapeutics with a rating of Outperform and set a new price target of $116.00 from $46.00 previously
ROTH MKM resumed coverage of Viking Therapeutics with a rating of Buy and set a new price target of $32.00
Maxim Group reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $25.00 from $15.00 previously
Stifel initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $22.00
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust Liver Fat Reductions, Histologic Results Demonstrating NASH/MASH Resolution and Fibrosis Improvement, and Promising Tolerability and Safety SAN DIEGO, Nov. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that final results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormo
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Dosing Regimen SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster present
SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. Details of the company's participation are as follows: Truist Healthcare ConferenceDetails: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: November 7, 2024Fireside Chat Timing: 12:30 – 1:00 p.m. Eastern on Thursday, Novembe
Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that clinical data from the company's VK2735 obesity program will be highlighted in two poster presentations at ObesityWeek® 2024, the annual meeting of the Obesity Society. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being develope
USA News Group News CommentaryIssued on behalf of PlantX Life Inc. VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's no wonder why analysts at SNS Insider are projecting the Weight Loss Drugs Market to grow at a whopping 43.73% CAGR through 2032. It's one of the fastest growing markets in pharmaceuticals, with nearly one in four employers saying they're either somewhat or very likely to begin covering the cost of anti-obesity medications within the next year. Health and wellness companies are responding in kind, with recent market developments coming
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on
Reductions in Very Long-Chain Fatty Acids and Plasma Lipid Levels Observed After 28 Days of Once Daily Dosing VK0214 Shown to be Safe and Well-Tolerated in 28-Day Study SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRβ), in patients with X-linked adrenoleukodystrophy (X-ALD). Results from this study showed VK0214 to be safe and well-tolerated following once-daily dosing
SAN DIEGO, Aug. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will be the featured speaker in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference. The conference will take place September 4-6, 2024, in New York City. Details are as follows: Morgan Stanley 22nd Annual Global Healthcare ConferenceDetails: Dr. Lian will participa
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 price target.
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
On Wednesday, major U.S. indices closed significantly lower. The Dow Jones Industrial Average fell 1.25% to 39,853.87, the S&P 500 dropped 2.3% to 5,427.13, and the Nasdaq declined 3.6% to 17,342.41. These are the top stocks that gained the attention of retail traders and investors throughout the day: Nvidia Corporation (NASDAQ:NVDA) Nvidia closed down 6.80% at $114.25, with an intraday high of $119.95 and a low of $113.44. The 52-week high is $140.76 and the low is $39.23. The company, along with other U.S. chip stocks, saw a significant selloff on Wednesday. This was partly due to disappointing second-quarter earnings from Tesla Inc and Google parent Alphabet Inc. Ford Motor Co
Viking Therapeutics, Inc. (NASDAQ:VKTX) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the key figures from the report. The Details: Viking Therapeutics reported quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%. Viking reported a net loss of $22.3 million for the second quarter, compared to a net loss of $19.2 million in the corresponding period in 2023. The increase in net loss for the three months ended June 30, 2024, was primarily due to the increase in research and development expenses and general and administrative expenses, noted previously, par
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent.
Viking Therapeutics (NASDAQ:VKTX) has outperformed the market over the past 5 years by 33.21% on an annualized basis producing an average annual return of 46.18%. Currently, Viking Therapeutics has a market capitalization of $5.73 billion. Buying $1000 In VKTX: If an investor had bought $1000 of VKTX stock 5 years ago, it would be worth $6,649.17 today based on a price of $51.93 for VKTX at the time of writing. Viking Therapeutics's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's
GLP-1 market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) faced a significant selloff on Thursday, as new weight-loss drugs from rival pharmaceutical companies began threatening the dominance of their flagship products, Zepbound and Wegovy. Shares of Eli Lilly plummeted by 6.3%, marking their worst daily performance since March 2021. In the last two sessions, they have dropped by over 10%, registering the worst two-day downside since March 2020. Similarly, shares of Dutch pharmaceutical giant Novo Nordisk A/S fell 4%. Chart: Eli Lilly’s Worst Session In Over Three Years Image: Benzinga Pro Weight-Loss Market Sees New Entrants “This week is a pr
Deep-pocketed investors have adopted a bearish approach towards Viking Therapeutics (NASDAQ:VKTX), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in VKTX usually suggests something big is about to happen. We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Viking Therapeutics. This level of activity is out of the ordinary. The general mood among these heavyweight investors is divided, with 0% leaning bullish and 77% bearish. Among these n
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin
Conference Call Scheduled for Wednesday, October 23 at 4:30 p.m. Eastern Time SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the third quarter 2024 after the market close on Wednesday, October 23, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on
Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti
Conference call scheduled for 4:30 p.m. ET today VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24Positive Biopsy Results From VK2809 Reported in June; End-of-Phase 2 Meeting in NASH/MASH Planned for 4Q24Enrollment Completed in Phase 1b Study of VK0214 for X-ALD; Data Expected 2H24In Vivo Data From Novel Amylin Agonist Program Reported at ADA in June; IND in Obesity Planned for 2025SAN DIEGO, July 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, tod
Conference Call Scheduled for Wednesday, July 24 at 4:30 p.m. Eastern Time SAN DIEGO, July 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter 2024 after the market close on Wednesday, July 24, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on Wedn
Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p<0.05) Up to 48% of VK2809-Treated Patients Achieved Both Resolution of NASH and a ≥1-Stage Improvement in Fibrosis as Compared to 20% for Placebo (p=0.01) Adverse Events, Including GI-Related AEs, Similar Among VK2809-Treated Patients vs. Placebo at Week 52; Consistent with Prior Data Reported at Week 12 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, June 3, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (
Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio. Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth," said Todd Davis, CEO of Ligand. "We continue to originate a robust pipe
Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO, April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We
Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 Trial in Obesity Planned for 2H24 Conference Call Scheduled for 8:00 a.m. ET Today SAN DIEGO, March 26, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive results from the company's Phase 1 multiple ascending dose (MAD) clinical trial of an oral tablet formulation of VK2735, a dual agonist of the glucagon-like peptide 1 (GL